clinical trials

Human Experimental Pain Models: A Review of Standardized Methods in Drug Development.

Human experimental pain models: A review of standardized methods in drug development.

J Res Med Sci. 2012 Jun; 17(6): 587-95
Reddy KS, Naidu MU, Rani PU, Rao TR

Human experimental pain models are essential in understanding the pain mechanisms… Continue reading →

Anthrax Lethal Toxin Downregulates Claudin-5 Expression in Human Endothelial Tight Junctions.

Anthrax lethal toxin downregulates claudin-5 expression in human endothelial tight junctions.

PLoS One. 2013; 8(4): e62576
D’Agnillo F, Williams MC, Moayeri M, Warfel JM

Vascular leakage pathologies such as pleural effusion and hemorrhage are hallmarks of anthrax pathogenesis. We… Continue reading →

Chlamydophila Pneumoniae Infection and Cardiovascular Disease.

Chlamydophila pneumoniae infection and cardiovascular disease.

N Am J Med Sci. 2013 Mar; 5(3): 169-81
Joshi R, Khandelwal B, Joshi D, Gupta OP

Atherosclerosis is a multifactorial vascular inflammatory process; however, the inciting cause for inflammation remains unclear. Two… Continue reading →

Antiaggressive Activity of Central Oxytocin in Male Rats.

Antiaggressive activity of central oxytocin in male rats.

Psychopharmacology (Berl). 2013 Apr 28;
Calcagnoli F, de Boer SF, Althaus M, den Boer JA, Koolhaas JM

RATIONALE: A substantial body of research suggests that the neuropeptide oxytocin promotes social affiliative… Continue reading →

Evaluation of Digoxin Concentration After Loading Dose in Patients With Renal Dysfunction.

Evaluation of digoxin concentration after loading dose in patients with renal dysfunction.

Can J Hosp Pharm. 2013 Mar; 66(2): 104-9
Pawlosky N, Macdonald E, Patel R, Kanji S

Loading dose recommendations for digoxin are based on the volume of… Continue reading →

A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs.

A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs.

Cancer Res. 2013 Apr 22;
Guerin E, Man S, Xu P, Kerbel RS

The failure rate of randomized phase III oncology clinical… Continue reading →

Safety and Efficacy of Deferasirox in the Management of Transfusion-Dependent Patients With Myelodysplastic Syndrome and Aplastic Anaemia: A Perspective Review.

Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.

Ther Adv Hematol. 2013 Apr; 4(2): 93-102
Adams RL, Bird RJ

Deferasirox is an orally administered, once-daily iron chelator… Continue reading →

Safety and Efficacy of Pralatrexate in the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Ther Adv Hematol. 2012 Aug; 3(4): 227-35
Marchi E, O’Connor OA

T-cell lymphomas (TCL) are a diverse and heterogeneous group of malignancies… Continue reading →

Successful Use of Cyclophosphamide as an Add-on Therapy for Multiple Myeloma Patients With Acquired Resistance to Bortezomib or Lenalidomide.

Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide.

Case Rep Hematol. 2013; 2013: 651902
Ito S, Oyake T, Murai K, Ishida Y

Novel agents such as thalidomide, lenalidomide,… Continue reading →

Ben Stasiewicz – Through Depression and Beyond


 

Ben Stasiewicz – Through Depression and Beyond – Ben Stasiewicz from Wellignton shares the story of his own journey through depression, how he came to personally know Jesus Christ, and what difference that …

 

There's a pill for… Continue reading →